Yujin Hoshida MD PhD
Hepatology & Liver Transplantation
Professor of Internal Medicine, Director of Liver Tumor Translational Research
Join to View Full Profile
5323 Harry Hines BlvdDallas, TX 75390
Phone+1 214-648-3111
Dr. Hoshida is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
OtherClass of 1994
Clinical Trials
- National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Roles: Contact
- Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Start of enrollment: 2023 May 10
Roles: Principal Investigator, Contact
- Erlotinib for Hepatocellular Carcinoma Chemoprevention
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsRisk stratification and early detection biomarkers for precision HCC screening.Yi-Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
Hepatology. 2023-07-01 - Precision HCC Surveillance: It Is All in the Number (Needed).Amit G Singal, Neehar D Parikh, Yujin Hoshida
Digestive Diseases and Sciences. 2023-03-01 - 23 citationsTreatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.Natascha Roehlen, Marion Muller, Zeina Nehme, Emilie Crouchet, Frank Jühling
Journal of Hepatology. 2023-02-01
Press Mentions
MedBlog Cancer; Digestive; Discovery Taking Aim at Fatty Liver, Cancer With New Blood TestSeptember 7th, 2022- A Simple Blood Test Reliably Predicts the Development of Liver Cancer – Healing PracticeJune 24th, 2022
- UTSW Researchers Identify a New Biomarker to Assess Your Risk of Liver CancerJune 6th, 2022
- Join now to see all
Grant Support
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Epigallocatechin gallate for prevention of lethal cirrhosis complicationsUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesUT SOUTHWESTERN MEDICAL CENTER2023–2028
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisUT SOUTHWESTERN MEDICAL CENTER2023–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Trial of Statins for Chemoprevention in Hepatocellular CarcinomaMASSACHUSETTS GENERAL HOSPITAL2021–2027
- Glycopathology of HCC: identification of the source cells of serum fucosylationMEDICAL UNIVERSITY OF SOUTH CAROLINA2019–2025
- Reverse-engineering precision liver cancer chemopreventionUT SOUTHWESTERN MEDICAL CENTER2019–2025
- Reverse-engineering precision liver cancer chemopreventionUT SOUTHWESTERN MEDICAL CENTER2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
